Research Article: The concentration of maternal sacubitril/valsartan transferred into human milk is negligible
Abstract:
Background: Peripartum cardiomyopathy (PPCM) is a common cause of heart failure (HF) in the peripartum. Some medications are considered safe while breastfeeding. However, sacubitril/valsartan (Entresto), while efficacious, is not recommended in breastfeeding women due to concerns about adverse infant development, and no published data suggest otherwise.
Introduction:
Objectives: This study aimed to assess the transfer of sacubitril/valsartan into human milk and evaluate the infant’s risk of drug exposure.
Read more